- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT06702592
Virtual Testis Cancer Lay Support and Survivorship Mål 2 (VITALSS)
Virtual Testicular Cancer Lay Support and Survivorship (VITALSS-studie) Mål 2
This study examines how virtual support can enhance well-being and survivorship in men with testicular cancer. Participants in North Carolina will be randomized into two groups: one with access to a virtual support platform and the other with access to patient educational materials only. After six months, the emotional well-being, self-efficacy, financial toxicity, and quality of life of both groups will be compared at 3 months and 6 months after baseline assessments.
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Studietype
Registrering (Antatt)
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiekontakt
- Navn: Deborah S Usinger
- Telefonnummer: 919-962-5431
- E-post: dusinger@email.unc.edu
Studer Kontakt Backup
- Navn: Taylor J Greene
- Telefonnummer: 919-962-5506
- E-post: taylor_greene@med.unc.edu
Studiesteder
-
-
North Carolina
-
Chapel Hill, North Carolina, Forente stater, 27599
- UNC Lineberger Comprehensive Cancer Center
-
Hovedetterforsker:
- Hung-Jui Tan, MD, MSHPM
-
Ta kontakt med:
- Deborah M Usinger
- Telefonnummer: 919-962-0000
- E-post: dusinger@email.unc.edu
-
Ta kontakt med:
- Taylor L Greene
- Telefonnummer: (919) 962-0000
- E-post: taylor_greene@med.unc.edu
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Men within 5 years of their initial diagnosis of germ cell testicular cancer.
- The subject is willing and able to comply with study procedures based on the judgment of the investigator.
- Adults aged 18-95 years old.
- Electronic informed consent was obtained to participate in the study.
Exclusion Criteria:
- Woman gender
- Non-English speaking
- Unwilling or unable to complete informed consent.
- On active treatment for another cancer.
- Actively receiving chemotherapy, radiation, or surgery for testicular cancer.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Helsetjenesteforskning
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Virtual support
Participants will have access to the virtual support platform. |
Subjects will use a virtual support platform that was built for their needs. |
|
Annen: Patient educational material
Participants will have access to patient educational material only. |
Participants will have access to patient educational material. |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Emotional well-being scores comparison
Tidsramme: At baseline, 3-months, and 6-months
|
Emotional well-being will be assessed by patient-reported outcomes questionnaires using a 9-item Positive Affect and Well-Being assessment from the Neuro-QOL Item Bank v1. Emotional well-being scores in virtual support and enhanced usual care will be compared. It is a 5-point Likert scale, higher scores reflect better emotional well-being. |
At baseline, 3-months, and 6-months
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Negative mental health comparison
Tidsramme: At baseline, 3-months, and 6-months
|
Negative mental health will be assessed by patient-reported outcomes questionnaires using 17 PROMIS items for anxiety, depression, loneliness, and stress. Negative mental health scores in virtual support and enhanced usual care will be compared. Scoring: Each item is rated on a 5-point scale between never (1) to always (5). The responses for each item are summed to get a total raw score. T-Scores: The raw score is then converted to a T-score using a scoring table specific to the PROMIS Anxiety item bank. T-scores standardize the results, making them comparable across different populations and studies. A T-score has a mean of 50 and a standard deviation of 10 in the general population. |
At baseline, 3-months, and 6-months
|
|
Social well-being, acceptance and inclusion comparison
Tidsramme: At baseline, 3-months, and 6-months
|
Social well-being will be assessed by patient-reported outcomes questionnaires using the 6-item Acceptance/Inclusion subscale of the General Belongingness Scale (GBS). GBS measures an individual's sense of belonging and social connectedness. It consists of 12 items that assess feelings of acceptance and inclusion. Each item is rated on a 7-point Likert scale (1 = Strongly Disagree and 7 = Strongly Agree). Higher scores reflect better inclusion. Scores in virtual support and enhanced usual care will be compared. |
At baseline, 3-months, and 6-months
|
|
Financial Toxicity comparison
Tidsramme: At baseline, 3-months, and 6-months
|
Financial Toxicity will be assessed by patient-reported outcomes questionnaires using a 12-item Comprehensive Score for Financial Toxicity (COST) instrument. Each item is rated on a 5-point Likert scale 0= = Not at all to 4= Very much. Higher scores indicate higher financial difficulties. Scores in virtual support and enhanced usual care will be compared. |
At baseline, 3-months, and 6-months
|
|
Self-efficacy comparison
Tidsramme: At baseline, 3-months, and 6-months
|
Self-efficacy will be assessed by patient-reported outcomes questionnaires using 20 PROMIS items for self-efficacy for managing daily activities, emotions, social interactions, and symptoms. Self-efficacy scores in virtual support and enhanced usual care will be compared. Each item is rated on a 5-point scale ( 1 = Never, 5 = Always). Responses are summed to get a total raw score for each domain. Raw scores are converted to T-scores using a scoring table. T-scores standardize results, with a mean of 50 and a standard deviation of 10 in the general population. |
At baseline, 3-months, and 6-months
|
|
Sexual Function and Satisfaction comparison
Tidsramme: At baseline, 3-months, and 6-months
|
Sexual Function and Satisfaction will be assessed by patient-reported outcomes questionnaires using a 20-item PROMIS SexFS instrument with domains for interest in sexual activity, global satisfaction with sex life, orgasm, and erectile function. Scores in virtual support and enhanced usual care will be compared. Each item is rated on a 5-point Likert scale: 1 = Not at all to 5= Very much. Raw scores are converted to T-scores using a scoring table specific to the PROMIS Sexual Function and Satisfaction profile. T-scores standardize the results, with a mean of 50 and a standard deviation of 10 in the general population.Higher T-scores indicate better sexual function and satisfaction. |
At baseline, 3-months, and 6-months
|
|
Functional well-being comparison Functional well-being comparison
Tidsramme: At baseline, 3-months, and 6-months
|
Functional well-being will be assessed by patient-reported outcomes questionnaires using a 7-item subscale of the Functional Assessment of Cancer Therapy (FACT-G) instrument. Each item is rated on a 5-point Likert scale, 0= = Not at all to 4= Very much. Higher scores indicate better well-being. Scores in virtual support and enhanced usual care will be compared. |
At baseline, 3-months, and 6-months
|
|
General Quality of Life comparison
Tidsramme: At baseline, 3-months, and 6-months
|
General Quality of Life will be assessed by patient-reported outcomes questionnaires using the PROMIS Global Health scale is an 8-item, validated survey that represents five core domains (physical function, pain, fatigue, emotional distress, social health). Two items each for physical and mental health as well as a question on quality of life will be administered. Scores in virtual support and enhanced usual care will be compared. Each item is rated on a 5-point Likert scale:1 = Poor to 5 = Excellent. Responses are summed to get a total raw score. The raw score is converted to a T-score using a scoring table. T-scores standardize the results, with a mean of 50 and a standard deviation of 10 in the general population. Higher T-scores indicate better overall health |
At baseline, 3-months, and 6-months
|
|
General Self-Efficacy comparison
Tidsramme: At baseline, 3-months, and 6-months
|
General Self-Efficacy will be assessed by patient-reported outcomes questionnaires using the 4-item PROMIS instrument that measures the respondent's belief in managing specific problems or issues. Each item is scored on a 5-point Likert scale, 1 = Never to 5 = Always. The raw score is then converted to a T-score using a scoring table specific to the PROMIS domain being measured. T-scores standardize the results, with a mean of 50 and a standard deviation of 10 in the general population. Higher T-scores indicate more of the concept being measured Scores in virtual support and enhanced usual care will be compared. |
At baseline, 3-months, and 6-months
|
|
Virtual platform usage
Tidsramme: At baseline, 3-months, and 6-months
|
Virtual platform usage will be assessed by time, visits, scrolling, posts, and messages spent on the virtual platform. |
At baseline, 3-months, and 6-months
|
|
Healthcare and supportive care utilization
Tidsramme: At baseline, 3-months, and 6-months
|
Self-reported use of healthcare and supportive care services will be assessed by a survey. Participants will be asked to quantify healthcare or other supportive care visits over the intervention period. |
At baseline, 3-months, and 6-months
|
Samarbeidspartnere og etterforskere
Samarbeidspartnere
Etterforskere
- Hovedetterforsker: Hung-Jui Tan, MD, UNC Lineberger Comprehensive Cancer Center
Publikasjoner og nyttige lenker
Hjelpsomme linker
Studierekorddatoer
Studer hoveddatoer
Studiestart (Antatt)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
- Urogenitale sykdommer
- Kjønnssykdommer
- Sykdommer i det endokrine systemet
- Genitale neoplasmer, hanner
- Urogenitale neoplasmer
- Neoplasmer etter nettsted
- Neoplasmer
- Kjønnssykdommer, mannlige
- Mannlige urogenitale sykdommer
- Atferdssymptomer
- Neoplasmer i endokrine kjertel
- Gonadal lidelser
- Stress, psykologisk
- Testikkelsykdommer
- Oppførsel
- Økonomisk stress
- Testikkelneoplasmer
Andre studie-ID-numre
- LCCC2418 AIM2
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .